Citation Impact
Citing Papers
2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
2018 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
Risk Factors for Bleeding during Treatment of Acute Venous Thromboembolism
1996
Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion
2010
Heparin-Protein Interactions
2002 Standout
Structure and Biological Activity of Heparin
1985
Binding of tissue plasminogen activator to human umbilical vein endothelial cells
1987
The heparanome and regulation of cell function: structures, functions and challenges
2008
Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin®) in the prophylaxis of thromboembolic complications of abdominal oncological surgery
1988
The Antithrombotic Activity and Pharmacokinetics of Enoxaparine, A Low Molecular Weight Heparin, In Humans Given Single Subcutaneous Doses of 20 to 80 mg
1988
A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis
1998 Standout
Maternal obesity and metabolic risk to the offspring: why lifestyle interventions may have not achieved the desired outcomes
2015
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
2001 Standout
Low-molecular-weight Heparins for the Treatment of Venous Thromboembolism
1993
Cellular and Molecular Characterization of the Adipose Phenotype of the Aromatase-Deficient Mouse
2003
The role of pathway-selective insulin resistance and responsiveness in diabetic dyslipoproteinemia
2012
Embolic strokes of undetermined source: the case for a new clinical construct
2014 Standout
Antithrombotic Therapy for VTE Disease
2016 Standout
Antithrombotic Therapy for Venous Thromboembolic Disease
1998
Treatment of Venous Thrombosis with Intravenous Unfractionated Heparin Administered in the Hospital as Compared with Subcutaneous Low-Molecular-Weight Heparin Administered at Home
1996
Subcutaneous Low-Molecular-Weight Heparin Compared with Continuous Intravenous Heparin in the Treatment of Proximal-Vein Thrombosis
1992 Standout
Lipoprotein lipase: from gene to obesity
2009
Prevention of VTE in Nonsurgical Patients
2012 Standout
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
Antithrombotic Therapy for VTE Disease
2012 Standout
Incidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism
2004 Standout
Low-molecular-weight heparin in pediatric patients with thrombotic disease: A dose finding study
1996
Fibroblast growth factor signalling: from development to cancer
2010 Standout
Mutation in blood coagulation factor V associated with resistance to activated protein C
1994 StandoutNature
Prevention of VTE in Nonorthopedic Surgical Patients
2012 Standout
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
2004 Standout
Prevention of Venous Thromboembolism
2004 Standout
Heparin and Low-Molecular-Weight Heparin
1998
How were new medicines discovered?
2011 Standout
Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer
2003 Standout
Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin
1995 Standout
Differential Regulation of Lipoprotein and Hepatitis C Virus Secretion by Rab1b
2017 StandoutNobel
Survey of the year 2003 commercial optical biosensor literature
2004
Prevention of Venous Thromboembolism
2008 Standout
Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
1991 Standout
Low-Molecular-Weight Heparin in Patients With Advanced Cancer: A Phase 3 Clinical Trial
2006
Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
1996
A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease
1997 Standout
Antithrombotic Therapy for Venous Thromboembolic Disease
2001 Standout
Subacute Recanalization and Reocclusion in Patients with Acute Ischemic Stroke Following Endovascular Treatment
2008
Survey of the year 2005 commercial optical biosensor literature
2006
A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients
1999 Standout
Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage
2015
Pharmacotherapeutic Aspects of Unfractionated and Low Molecular Weight Heparins
1990
Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions
2009
Venous Thromboembolism in Spinal Cord Injury Patients
1992
Stem cell-derived polarized hepatocytes
2020 StandoutNobel
Adipose Tissue as an Endocrine Organ
2004 Standout
Chronic Intermittent Hypoxia Induces Atherosclerosis via Activation of Adipose Angiopoietin-like 4
2013 StandoutNobel
Guidelines for the Early Management of Adults With Ischemic Stroke
2007 Standout
Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. A comparison between unfractionated and low-molecular-weight heparin.
1994
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
2002 Standout
Mechanisms of Insulin Action and Insulin Resistance
2018 Standout
Regulation of the endothelial cell urokinase-type plasminogen activator receptor. Evidence for cyclic AMP-dependent and protein kinase C-dependent pathways.
1993 StandoutNobel
Low-affinity heparin potentiates the action of high-affinity heparin oligosaccharides
1984
Plasminogen Activators, Tissue Degradation, and Cancer
1985 Standout
The effect of heparin fragments of different molecular weights on experimental thrombosis and haemostasis
1985
Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack
2006 Standout
Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association.
1994
Intrahepatic Role of Exchangeable Apolipoproteins in Lipoprotein Assembly and Secretion
2012
Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.
1989
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
2011 Standout
Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity
2016 Standout
Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions
2010
Contributions of Amino Acid Side Chains to the Kinetics and Thermodynamics of the Bivalent Binding of Protein L to Ig κ Light Chain
2004 StandoutNobel
A Randomized Double-Blind Study Between a Low Molecular Weight Heparin Kabi 2165 and Standard Heparin in the Prevention of Deep Vein Thrombosis in General Surgery
1988
Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells.
1990 StandoutNobel
Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery
1988
Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis
1986
Surface Plasmon Resonance Sensors for Detection of Chemical and Biological Species
2008 Standout
Low-Molecular-Weight Heparins
1997 Standout
The Metabolic Syndrome
2008 Standout
Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group.
1994
Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium.
1988 Standout
The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin-activated plasma
1988
Tumors: Wounds That Do Not Heal
1986 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack
2010 Standout
Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis
2005 Standout
Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers
1986
Antithrombotic Therapy for Venous Thromboembolic Disease
1995
Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously
1983
Subcutaneous Low-Molecular-Weight Heparin Compared With Continuous IntravenoUnfractionated Unfractionated Heparin in the Treatment of Proximal Deep Vein Thrombosis
1993
Works of Solveig Nilsson being referenced
Maternal Obesity Is Associated With the Formation of Small Dense LDL and Hypoadiponectinemia in the Third Trimester
2013
Functional Analyses of Human Apolipoprotein CII by Site-directed Mutagenesis
2002
Structure and Dynamics of Human Apolipoprotein CIII
2008
Apolipoprotein A-V-heparin Interactions
2005
Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits
1982
Turnover of tissue plasminogen activator in normal and hepatectomized rabbits
1985
Human extrinsic plasminogen activator fibrinolytic properties and neutralization in vivo
1983